OQROGet OQRO Pro
Insider trade

Merck (MRK)Chief Marketing Officer sold ~$1.21M

Chirfi Guindo, Chief Marketing Officer at Merck, sold ~$1.21M of Merck shares.

~$1.21M
Approx. value · 10K sh @ $121.46
61K
Holds after · shares reported
Traded
Feb 12, 2026
Filed
Feb 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 18, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  2. Dec 18, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  3. Dec 19, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  4. Jan 13, 2026Federal contract · $96K obligatedDepartment of Veterans Affairs awarded Merck: $96K obligated to date
  5. Jan 27, 2026FDAFDA drug approval: Noxafil
  6. Jan 27, 2026FDAFDA drug approval: Noxafil
  7. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  8. Feb 4, 2026Insider · 4 peopleInsiders: 6 sales (~$13.2M)
  9. Feb 4, 2026CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  10. Feb 5, 2026InsiderOfficer sold ~$2.44M of MRK shares in the open market
  11. Feb 6, 2026Insider · 3 peopleInsiders: 3 sales (~$7.0M)
  12. Feb 9, 2026Insider · 2 peopleInsiders: 4 sales (~$15.7M)
  13. Feb 10, 2026FDAFDA drug approval: Keytruda
  14. Feb 10, 2026FDAFDA drug approval: Keytruda Qlex
  15. Feb 10, 2026InsiderOfficer sold ~$1.2M of MRK shares in the open market
  16. Feb 12, 2026 · this disclosureInsiderOfficer sold ~$1.21M of MRK shares in the open market

What came next

  1. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  2. Apr 15, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  3. Apr 24, 2026FDAFDA drug approval: Keytruda Qlex
  4. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  5. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  6. May 4, 2026Federal contract · $43K obligatedDepartment of Veterans Affairs awarded Merck: $43K obligated to date
  7. May 8, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  8. May 11, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  9. May 11, 2026Federal contract · $342K obligatedDepartment of Veterans Affairs awarded Merck: $342K obligated to date
  10. May 21, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
  11. Jun 12, 2026FDAFDA drug approval: Welireg
  12. Jun 12, 2026FDAFDA drug approval: Keytruda
  13. Jun 12, 2026FDAFDA drug approval: Keytruda Qlex
  14. Jun 12, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 123 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Chirfi Guindo, Chief Marketing Officer

The full history of Chirfi Guindo, Chief Marketing Officer is on the profile page.

How this filing works

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data